

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/20, 31/40, 31/215, 31/19, 31/135		A1	(11) International Publication Number: WO 96/18386
			(43) International Publication Date: 20 June 1996 (20.06.96)
(21) International Application Number: PCT/IE95/00062			(74) Agents: O'CONNOR, Donal, H. et al.; Cruickshank & Co., 1 Holles Street, Dublin 2 (IE).
(22) International Filing Date: 14 December 1995 (14.12.95)			
(30) Priority Data:			
940969 14 December 1994 (14.12.94) IE			
940971 14 December 1994 (14.12.94) IE			
950583 31 July 1995 (31.07.95) IE			(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DE (Utility model), DK, DK (Utility model), EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).
950584 31 July 1995 (31.07.95) IE			
950586 31 July 1995 (31.07.95) IE			
(71) Applicants (for all designated States except US): ENBALT TRADING LIMITED [IE/IE]; Setanta Centre, 4th floor, Nassau Street, Dublin 2 (IE). BIOGLAN IRELAND (R & D) LIMITED [IE/IE]; 1 Stokes Place, Saint Stephens Green, Dublin 2 (IE).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): McCARTHY, Paul [IE/IE]; Ballyvaughan, Clonmel, County Tipperary (IE). DONEGAN, Ann [IE/IE]; 8 Cloughcarigeen, Kilsheelan, County Tipperary (IE). PATTISON, John [IE/IE]; 52 Hazelwood, Shankill, County Dublin (IE). O'SULLIVAN, Richard [IE/IE]; 15 Melitta Park, Kildare, County Kildare (IE).			
(54) Title: PHARMACEUTICAL TABLET FORMULATIONS FOR DIRECT COMPRESSION			
(57) Abstract			
<p>Tablets are produced by directly compressing a mixture formed by dry blending an active pharmaceutical ingredient, direct compression lactose, a lubricant such as magnesium stearate and an inhibitor, especially maize starch. The active pharmaceutical ingredient includes oxybutynin, bumetanide, indapamide and particularly selegiline. The inhibitor prevents interaction between the direct compression lactose and the active pharmaceutical ingredient.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

Pharmaceutical tablet formulations for direct compression

The invention relates to a pharmaceutical tablet formulation of an active pharmaceutical ingredient and to a method for producing such tablets.

UK-A-1,153,578 describes selegiline hydrochloride which is
5 the compound of the formula



10 It has 5 monoamine oxidase inhibitor activity and is used in the treatment of Parkinsons disease and as a coronary dilator, hallucinogenic and anti-depressive agent and also as a tranquilliser, analgesic and an appetite suppressant.

15 It is known to formulate selegiline in tablet form using conventional wet granulation techniques. However, to date it has not been possible to produce a satisfactory tablet composition of selegiline by direct compression techniques. Similar problems have arisen with other active pharmaceutical ingredients.

20 Direct compression is the preferred technique since it is considered that fewer chemical stability problems are associated with this technique in comparison with the wet granulation process as moisture is considered to be a primary cause of instability in tablet dosage forms. In
25 addition to the advantage of improved active ingredient stability, the use of direct compression makes it unnecessary to use applied heat to dry the damp granule. Other benefits associated with direct compression are related to particle size uniformity.

- 2 -

This invention therefore is directed towards a direct compression pharmaceutical tablet formulation of an active pharmaceutical ingredient.

5 According to the invention, there is provided a direct compression pharmaceutical tablet formulation comprising:

an active pharmaceutical ingredient,

a direct compression excipient which interacts with the active pharmaceutical ingredient, and

10 an amount of an inhibitor to reduce the interaction between the direct compression excipient and the active pharmaceutical ingredient.

In a preferred embodiment of the invention the formulation contains an amount of the inhibitor to substantially prevent the interaction between the direct compression
15 excipient and the active pharmaceutical ingredient.

In one preferred embodiment of the invention the weight ratio of inhibitor to the active pharmaceutical ingredient is from 1:50 to 4:1, ideally from 8:5 to 12:5. Preferably the inhibitor includes a starch, starch-derived or
20 cellulose-derived product, especially maize starch.

In another embodiment of the invention, the inhibitor includes a crospovidone based product.

In a preferred embodiment of the invention the excipient is direct compression lactose and/or microcrystalline
25 cellulose.

- 3 -

The weight ratio of direct compression lactose to active pharmaceutical ingredient is preferably from 2:1 to 100:1 most preferably from 7:1 to 50:1, ideally from 8:1 to 11:1.

- 5 The weight ratio of microcrystalline cellulose to active pharmaceutical ingredient is preferably from 2:1 to 100:1, most preferably from 3:1 to 17:1, ideally from 4:1 to 16:1.

- 10 In one embodiment of the invention, the formulation includes a lubricant, preferably from 0.1% to 5%, most preferably approximately 0.25% by weight of the formulation. The lubricant may be magnesium stearate, zinc stearate, calcium stearate, stearic acid or combinations of these materials.

- 15 In one embodiment of the invention, the formulation includes an antioxidant or other suitable stabiliser to enhance the stability of the tablet formulation. Preferably the antioxidant is present in an amount of from 0.5% to 2% by weight of the formulation.

- 20 In another embodiment of the invention the formulation may include glidants, disintegrants, fillers, wetting agents, stabilisers, binders, or combinations of these materials.

- 25 The active pharmaceutical ingredient may be selegiline or a pharmaceutically acceptable salt thereof, preferably selegiline hydrochloride. The active pharmaceutical ingredient may also be other compounds including oxybutynin or a pharmaceutically acceptable salt thereof, preferably oxybutynin chloride; bumetanide or a pharmaceutically acceptable salt thereof; or indapamide or
30 a pharmaceutically acceptable salt thereof, preferably indapamide hemihydrate.

- 4 -

The invention also provides a method of preparing a tablet by preparing a formulation according to the invention and directly compressing said formulation to form a tablet.

5 The invention further provides a method for producing tablets of an active pharmaceutical ingredient comprising the steps of:-

10 mixing the active pharmaceutical ingredient, a lubricant, a direct compression excipient, and an amount of an inhibitor to substantially prevent interaction between the direct compression lactose and the active pharmaceutical ingredient; and

directly compressing the mixture thus formed to form tablets.

15 Preferably the formulation includes a lubricant and the method includes the step of mixing the ingredients except the lubricant and subsequently adding the lubricant. Preferably the mixing is a dry blending technique. The excipient is preferably direct compression lactose.

20 The inhibitor preferably includes a starch, starch-derived or cellulose-derived product. Alternatively, the inhibitor includes a crospovidone based product.

The invention will be more clearly understood from the following description thereof given by way of example only.

25 In each case, the formulation is a direct compression formulation. The ingredients were weighed out and all the ingredients except the lubricant were added to a receptacle and dry blended for about 6 minutes. The

- 5 -

lubricant (in these cases magnesium stearate) was then added and the mixture is blended for a further 2 minutes. Tablets were then formed from the blend by conventional direct compression techniques.

5 In Examples A and 1 to 4, selegiline hydrochloride was used as the active ingredient. However, it will be appreciated that selegiline base or any pharmaceutically acceptable salt thereof may be used as the active ingredient. Similar comments apply to the examples
10 referring to other active ingredients. In examples B and 5 oxybutynin chloride was used. In example 9 indapamide hemihydrate was used.

All of the excipients used in the examples are of pharmaceutical grade.

15 Magnesium Stearate: consists mainly of magnesium stearate with variable proportions of magnesium palmitate and/or magnesium oleate. It is a tablet
20 lubricant.

Zinc Stearate: consists mainly of zinc stearate with variable proportions of zinc palmitate and zinc oleate. It is a
25 tablet lubricant.

Sodium Lauryl Sulfate: an anionic surfactant used as a detergent and wetting agent in tablet formulations.

- 6 -

Croscarmellose Sodium: is a cross-linked polymer of carboxymethylcellulose sodium. It is a tablet disintegrant.

5 Sodium Starch Glycolate: is the sodium salt of a poly- α -glucopyranose in which some of the hydroxyl groups are in the form of carboxymethyl ether. It is a tablet disintegrant.

10 Crospovidone: is a water insoluble synthetic cross-linked homopolymer of N-vinyl-2-pyrrolidone. It is a tablet disintegrant.

15 Microcrystalline Cellulose: is a purified, partially depolymerised cellulose and is used as a diluent and has some lubricant and disintegrant properties.

20 Direct Compression Lactose (DC Lactose): is direct compression grade of lactose which is more fluid and more compressible than crystalline or powdered lactose.

25 Various proprietary brands of direct compression lactose are commercially available. In the examples given below, the brand of direct compression lactose used was Tablettose 80 available from Meggle GmbH of Germany. We have also achieved similar results using Pharmatose DC11 which is available from DMV International of The
30 Netherlands.

- 7 -

It will be appreciated that various similar formulations to those described below may be prepared by scaling up or down the components of the mixture so that the new formulation is quantitatively proportional to those given below. For example, formulations containing 10 mgs of selegiline may be prepared in this way. Similarly, an oxybutynin formulation may be prepared in this way with 2.5 mg rather than 5 mg of active. In addition, a bumetanide formulation may also be prepared in this way with 1 mg rather than 5 mg of active ingredient.

- 8 -

EXAMPLE A

A batch of tablets were prepared by direct compression.
Each tablet had the following composition:-

	5 mg	selegiline hydrochloride
5	85 mg	DC Lactose

The tablets gave an assay of 91.8%.

This example illustrates the low assay that results when tablets of selegiline are manufactured by direct compression techniques using direct compression lactose.

10 **EXAMPLE 1**

A batch of tablets were prepared by direct compression.
Each tablet had the following composition:-

	5 mg	selegiline hydrochloride
	52.75 mg	DC Lactose
15	24 mg	microcrystalline cellulose
	8 mg	maize starch
	0.25 mg	magnesium stearate

The tablets gave an assay of 99.5%.

20 It will be noted that the use of an inhibitor, in this case maize starch, radically improves the assay result.

- 9 -

EXAMPLE 2

A batch of tablets were prepared by direct compression. Each tablet had the following composition:-

	5 mg	selegiline hydrochloride
5	48.75 mg	DC Lactose
	24 mg	microcrystalline cellulose
	12 mg	maize starch
	0.25 mg	magnesium stearate

The tablets gave an assay of 97.94%.

- 10 Using a larger amount of maize starch and less DC Lactose did not significantly effect the assay.

EXAMPLE 3

A batch of tablets were prepared by direct compression. Each tablet had the following composition:-

15	5 mg	selegiline hydrochloride
	48.75 mg	DC Lactose
	24 mg	microcrystalline cellulose
	11 mg	maize starch
	1 mg	citric acid
20	0.25 mg	magnesium stearate

The tablets gave an assay of 99.6%.

The addition of an antioxidant, in this case citric acid, is to counteract any oxidation reactions in storage.

- 10 -

EXAMPLE 4

A batch of tablets were prepared by direct compression. Each tablet had the following composition:-

	5 mg	selegiline hydrochloride
5	49.45 mg	Direct Compression Lactose
	24 mg	Microcrystalline Cellulose
	11 mg	Maize Starch
	0.55 mg	Zinc Stearate

The tablets gave an assay of 100.7%

- 10 From extensive research and development in producing tablets of selegiline by direct compression techniques, we have noticed a very significant interaction between selegiline hydrochloride and conventional bulking agents such as DC Lactose and microcrystalline cellulose. It has
- 15 not been possible using conventional formulations to produce a tablet of selegiline by direct compression without a very significant adverse affect on the assay results for the tablets produced. In all cases, the assay was found to be less than 95%, in some cases, as low as
- 20 70%. It is not fully understood why such poor assay results were obtained. It is, however, speculated that there may be an interaction between the selegiline and the DC Lactose and microcrystalline cellulose, resulting possibly in the formation of a complex which adversely
- 25 affects the amount of selegiline detectable or available on assay. We have surprisingly found that the interaction is avoided and good assay results are obtained if an inhibitor, particularly maize starch, is incorporated especially in the amounts mentioned above.
- 30 It will be appreciated that it may be possible to use direct compression excipients either in addition to or as

- 11 -

an alternative either to direct compression lactose or microcrystalline cellulose. Such direct compression excipients include calcium hydrogen phosphate, compressible sugar, dextrates, and pregelatinized starch.

- 5 It will be appreciated that the formulation may include any suitable lubricant such as magnesium stearate or zinc stearate as described above or other stearic acid salts such as calcium stearate. Other suitable lubricants may also be incorporated, including glyceryl monostearate,
- 10 glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil type 1, light mineral oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulphate, sodium stearyl fumarate, stearic acid and talc.
- 15 It will also be appreciated that while the presence of an antioxidant may not be essential, in cases where such an antioxidant is used it may be selected from one or more of the following: alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated
- 20 hydroxytoluene, citric acid, fumaric acid, malic acid, propylgallate, sodium ascorbate, sodium metabisulphite.

- We have also found that the interactions described above also apply to other active pharmaceutical ingredients. The following examples illustrate how similar techniques
- 25 may also be applied to direct compression pharmaceutical tablet formulations of active ingredients other than selegiline.

- 12 -

EXAMPLE B - COMPARISON

A batch of tablets were prepared by direct compression.
Each tablet had the following composition:-

5	5 mg	oxybutynin chloride
	174 mg	DC Lactose
	1 mg	Magnesium Stearate

The tablets gave an assay of 88.3%.

EXAMPLE 5

10 A batch of tablets were prepared by direct compression.
Each tablet had the following composition:-

15	5 mg	oxybutynin chloride
	119 mg	DC Lactose
	43 mg	microcrystalline cellulose
	12 mg	crospovidone
	1 mg	magnesium stearate

The tablets gave an assay of 97.9%.

- 13 -

EXAMPLE C - COMPARISON

A batch of tablets were prepared by direct compression.
Each tablet had the following composition.

	5 mg	bumetanide
5	343 mg	DC Lactose
	2 mg	magnesium Stearate

The tablets gave an assay of 91%.

EXAMPLE D - COMPARISON

A batch of tablets were prepared by direct compression.
10 Each tablet had the following composition.

	5 mg	bumetanide
	343 mg	microcrystalline cellulose
	2 mg	magnesium stearate

The tablets gave a assay of 93.7%.

15 **EXAMPLE 6**

A batch of tablets were prepared by direct compression.
Each tablet had the following composition.

	5 mg	bumetanide
	237.5 mg	DC Lactose
20	80 mg	microcrystalline cellulose
	25 mg	crospovidone
	2.5 mg	magnesium stearate

The tablets gave an assay of 97.4%.

- 14 -

EXAMPLE 7

A batch of tablets were prepared by direct compression.
Each tablet had the following composition.

	5 mg	bumetanide
5	237.5 mg	DC Lactose
	80 mg	microcrystalline cellulose
	25 mg	maize starch
	2.5 mg	magnesium stearate

The tablets gave an assay of 98.2%.

EXAMPLE 8

A batch of tablets were prepared by direct compression.
Each tablet had the following composition.

	5 mg	bumetanide
	241 mg	DC Lactose
15	80 mg	microcrystalline cellulose
	17 mg	croscarmellose sodium
	5 mg	sodium lauryl sulphate
	2 mg	magnesium stearate

The tablets gave an assay of 97.9%

EXAMPLE 9

A batch of tablets were prepared by direct compression.
Each tablet had the following composition:-

	2.5 mg	indapamide hemihydrate
	82.75 mg	DC Lactose
25	4 mg	carboxymethyl starch
	0.75 mg	magnesium stearate.

- 15 -

The tablets gave an assay of 100.4%.

It will be appreciated that similar techniques may be applied to produce direct compression tablet formulations of other active pharmaceutical ingredients which interact
5 with direct compression excipients.

The invention is not limited to the embodiments hereinbefore described which may be varied in detail.

- 16 -

CLAIMS

1. A direct compression pharmaceutical tablet formulation comprising:

an active pharmaceutical ingredient,

5 a direct compression excipient which interacts with the active pharmaceutical ingredient,

and an amount of an inhibitor to reduce the interaction between the direct compression excipient and the active pharmaceutical ingredient.
10
2. A direct compression pharmaceutical tablet formulation as claimed in claim 1 wherein the formulation contains an amount of the inhibitor to substantially prevent the interaction between the
15 direct compression excipient and the active pharmaceutical ingredient.
3. A formulation as claimed in claim 1 or 2 wherein the weight ratio of inhibitor to the active pharmaceutical ingredient is from 1:50 to 4:1.
- 20 4. A formulation as claimed in any of claims 1 to 3 wherein the weight ratio of inhibitor to the active pharmaceutical ingredient is from 8:5 to 12:5.
5. A formulation as claimed in any preceding claim wherein the inhibitor includes a starch, starch-derived or cellulose-derived product.
25
6. A formulation as claimed in any preceding claim wherein the inhibitor includes a maize starch.

- 17 -

7. A formulation as claimed in any proceeding claim in which the inhibitor includes a crospovidone based product.
- 5 8. A formulation as claimed in any preceding claim wherein the excipient includes direct compression lactose.
9. A formulation as claimed in claim 8 wherein the weight ratio of direct compression lactose to the active pharmaceutical ingredient is from 2:1 to 100:1.
10
10. A formulation as claimed in claim 8 or 9 wherein the weight ratio of direct compression lactose to the active pharmaceutical ingredient is from 7:1 to 50:1.
11. A formulation as claimed in any of claims 8 to 10 wherein the weight ratio of direct compression lactose to the active pharmaceutical ingredient is from 8:1 to 11:1.
15
12. A formulation as claimed in any preceding claim wherein the excipient includes microcrystalline cellulose.
20
13. A formulation as claimed in claim 12 wherein the weight ratio of microcrystalline cellulose to active pharmaceutical ingredient is from 2:1 to 100:1.
14. A formulation as claimed in claim 12 or 13 wherein the weight ratio of microcrystalline cellulose to active pharmaceutical ingredient is from 3:1 to 17:1.
25

- 18 -

15. A formulation as claimed in any of claims 12 to 14 wherein the weight ratio of microcrystalline cellulose to active pharmaceutical ingredient is from 4:1 to 16:1.
- 5 16. A formulation as claimed in any preceding claim including a lubricant.
17. A formulation as claimed in claim 16 wherein the lubricant is present in an amount from 0.1% to 5% by weight of the formulation.
- 10 18. A formulation as claimed in claim 17 wherein the lubricant is present in an amount of approximately 0.25% by weight of the formulation.
- 15 19. A formulation as claimed in any preceding claim including an antioxidant or other suitable stabiliser to enhance the stability of the tablet formulation.
- 20 20. A formulation as claimed in claim 19 wherein the antioxidant is present in an amount from 0.5% to 2% by weight of the formulation.
- 20 21. A formulation as claimed in any proceeding claim including either a glidant, a disintegrant, a filler, a wetting agent, stabiliser, a binder or any combination of these materials.
- 25 22. A formulation as claimed in any preceding claim wherein the active pharmaceutical ingredient is selegiline or a pharmaceutically acceptable salt thereof, preferably selegiline hydrochloride.
23. A formulation as claimed in any of claims 1 to 21 wherein the active pharmaceutical ingredient is

- 19 -

oxybutynin or a pharmaceutically acceptable salt thereof, preferably oxybutynin chloride.

24. A formulation as claimed in any of claims 1 to 21
5 wherein the active pharmaceutical ingredient is
bumetanide or a pharmaceutically acceptable salt
thereof.
25. A formulation as claimed in any of claims 1 to 21
10 wherein the active pharmaceutical ingredient is
indapamide or a pharmaceutically acceptable salt
thereof, preferably indapamide hemihydrate.
26. A direct compression pharmaceutical tablet
formulation substantially as hereinbefore described
with reference to examples 1 to 3.
27. A direct compression pharmaceutical tablet
15 formulation substantially as hereinbefore described
with reference to example 4.
28. A direct compression pharmaceutical tablet
formulation substantially as hereinbefore described
with reference to example 5.
- 20 29. A direct compression pharmaceutical tablet
formulation substantially as hereinbefore described
with reference to examples 6, 7 and 8.
30. A direct compression pharmaceutical tablet
25 formulation substantially as hereinbefore described
with reference to example 9.
31. A method of preparing a tablet comprising:

directly compressing said formulation into a tablet.

- 5 32. A method for producing tablets of an active
pharmaceutical ingredient comprising the steps of:-
- 10 mixing the active pharmaceutical ingredient, a
lubricant, a direct compression excipient, and
an amount of an inhibitor to reduce interaction
between the direct compression excipient and the
active pharmaceutical ingredient; and
- directly compressing the mixture thus formed to
form tablets.
- 15 33. A method as claimed in claim 32 wherein the method
includes the step of mixing the ingredients except
the lubricant; subsequently adding the lubricant; and
further mixing the ingredients.
34. A method as claimed in claim 32 or 33 wherein the
mixing is performed using a dry blending technique.
- 20 35. A method as claimed in any of claims 32 to 34 wherein
the direct compression excipient includes direct
compression lactose.
36. A method as claimed in any of claims 32 to 35 wherein
the inhibitor includes a starch, a starch-derived
25 product, a cellulose-derived product or a derivative
thereof.

- 21 -

37. A method as claimed in any of claims 32 to 36 wherein the inhibitor includes a crospovidone based product.
38. A method as claimed in any of claims 31 to 37 wherein the active pharmaceutical ingredient is selegiline or
5 a pharmaceutically acceptable salt thereof, preferably selegiline hydrochloride.
39. A method for producing tablets of an active pharmaceutical ingredient substantially as
10 hereinbefore described with reference to examples 1 to 9.
40. A method for producing tablets of selegiline substantially as hereinbefore described with reference to examples 1 to 4.
41. A method for producing tablets of oxybutynin
15 substantially as hereinbefore described with reference to example 5.
42. A method for producing tablets of bumetanide substantially as hereinbefore described with reference to examples 6, 7 and 8.
- 20 43. A method for producing tablets of indapamide substantially as hereinbefore described with reference to example 9.
44. Tablets of an active pharmaceutical ingredient whenever produced by a method as claimed in any of
25 claims 31 to 43.
45. Tablets of selegiline or a pharmaceutically acceptable salt thereof, preferably selegiline

- 22 -

hydrochloride whenever produced by a method as claimed in any of claims 31 to 40.

- 5 46. Tablets of oxybutynin or a pharmaceutically acceptable salt thereof, preferably oxybutynin chloride whenever produced by a method as claimed in any of claims 31 to 39 or 41.
47. Tablets of bumetanide or a pharmaceutically acceptable salt thereof whenever produced by a method as claimed in any of claims 31 to 39 or 42.
- 10 48. Tablets of indapamide or a pharmaceutically acceptable salt thereof, preferably indapamide hemihydrate whenever produced by a method as claimed in any of claims 31 to 39 or 43.
- 15 49. A tablet prepared or preparable from a formulation as claimed in any of claims 1 to 30.

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/IE 95/00062

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/20 A61K31/40 A61K31/215 A61K31/19 A61K31/135

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 08463 (RHONE POULENC RORER SA) 29 May 1992	1-3,5, 12,16, 17,31, 32,34, 36,44,49
Y	see page 7; example 2 see above	4,6-11, 13-15, 18-30, 33,35, 37-43, 45-48

	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *a* document member of the same patent family

Date of the actual completion of the international search

25 March 1996

Date of mailing of the international search report

07. 05. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

Int. .ional Application No
PCT/IE 95/00062

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 511 767 (MERCK & CO INC) 4 November 1992	1-3,5,8, 12,16, 17, 31-36, 44,49
Y	see page 2, line 27 - line 29 see page 5 - page 6; examples 1-12 see above	4,6,7, 9-11, 13-15, 18-30, 37-43, 45-48
X	--- US,A,5 358 941 (BECHARD SIMON R ET AL) 25 October 1994	1-3,5, 8-10, 12-17, 21, 31-36, 44,49
Y	see column 4 - column 5; examples 1-3 see column 4, line 15 see above	4,6,7, 11, 18-20, 22-30, 37-43, 45-48
X	--- EP,A,0 298 666 (AMERICAN HOME PROD) 11 January 1989	1-3,5, 16-18, 31,44,49
Y	see page 2, line 1 - line 8 see page 3 - page 9; examples 1-7 see above	4,6-11, 13-15, 19-30, 33,35, 37-43, 45-48
Y	--- WO,A,94 22435 (ORION YHTYMAE OY ;HALONEN MATTI AUKUSTI (FI); LEINONEN ULLA INKERI) 13 October 1994 see the whole document	22,26, 27,39,40
Y	--- EP,A,0 519 820 (ADIR) 23 December 1992 see the whole document	25,30,43
Y	--- WO,A,93 23025 (ALZA CORP) 25 November 1993 see the whole document	24,29,42
1 1 Y	--- DE,A,39 41 703 (SANOL ARZNEI SCHWARZ GMBH) 20 June 1991 see the whole document -----	23,28,41

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IE 95/00062

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO-A-9208463	29-05-92	FR-A-	2669221	22-05-92
		AT-T-	111734	15-10-94
		CA-A-	2094122	16-05-92
		DE-D-	69104220	27-10-94
		DE-T-	69104220	26-01-95
		EP-A-	0557389	01-09-93
		ES-T-	2060417	16-11-94
		JP-T-	6502420	17-03-94

EP-A-0511767	04-11-92	AU-B-	1522992	05-11-92
		CA-A-	2067307	30-10-92
		CN-A-	1066184	18-11-92
		CZ-A-	9302270	16-03-94
		JP-A-	6157309	03-06-94
		NO-A-	933806	22-10-93
		NZ-A-	242486	23-12-93
		SK-A-	117793	11-05-94
WO-A-	9219228	12-11-92		

US-A-5358941	25-10-94	AU-B-	5611594	22-06-94
		CN-A-	1098907	22-02-95
		CZ-A-	9501346	18-10-95
		EP-A-	0690719	10-01-96
		FI-A-	952685	01-06-95
		NO-A-	952184	01-06-95
		PL-A-	309245	02-10-95
		WO-A-	9412200	09-06-94
ZA-A-	9308979	03-08-94		

EP-A-0298666	11-01-89	DE-A-	3883098	16-09-93
		DE-T-	3883098	02-12-93
		ES-T-	2058288	01-11-94
		IE-B-	61676	30-11-94
		US-A-	4904477	27-02-90

WO-A-9422435	13-10-94	AU-B-	4023695	15-02-96
		AU-B-	663995	26-10-95
		AU-B-	6430094	24-10-94
		CA-A-	2137164	13-10-94
		EP-A-	0643578	22-03-95

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/IE 95/00062

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9422435		FI-A- 945716 JP-T- 7506845 NO-A- 944631 NZ-A- 263568	02-12-94 27-07-95 01-12-94 26-01-96
EP-A-0519820	23-12-92	FR-A- 2677886 AT-T- 131050 AU-B- 651894 AU-B- 1834392 CA-A- 2071408 DE-D- 69206495 JP-A- 5186346 US-A- 5334392 ZA-A- 9204482	24-12-92 15-12-95 04-08-94 24-12-92 19-12-92 18-01-96 27-07-93 02-08-94 18-08-93
WO-A-9323025	25-11-93	AU-B- 666735 AU-B- 4247393 CA-A- 2132865 FI-A- 945311 NO-A- 944249 US-A- 5411740 ZA-A- 9303349	22-02-96 13-12-93 25-11-93 11-11-94 14-11-94 02-05-95 15-06-94
DE-A-3941703	20-06-91	NONE	